Samir Ounzain, PhD, is a molecular biologist with over 15 years of experience in studying the genome's dark matter and its impact on development and disease. He is the CEO and Co-Founder of HAYA Therapeutics, a company developing RNA-guided therapeutics targeting the regulatory genome for conditions like fibrosis. Prior to founding HAYA, Dr. Ounzain was a Project Leader and Research Fellow at Lausanne University Hospital (CHUV), Switzerland. His research has led to the discovery of heart-enriched long non-coding RNAs, including CARMEN, Meteor, and Wisper, advancing the field of precision and genomic medicine.